glp·helper
glphelper.com/tirzepatide/florida/weston
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Weston, FL

Verified Tirzepatide providers in Weston, FL. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
33
as of today
§ 02Provider directory: Florida
33 of 33 shown

Find a Tirzepatide provider in Florida.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by Florida city · /tirzepatide/florida/{city}
§ 03Getting Tirzepatide in Weston
33 providers · Weston, FL

How to get Tirzepatide in Weston.

33 GLP-1 prescribers and 7 local resource types are on record for Weston, plus 3 nearby towns in the directory.

Prescribers in Weston
33 prescribers
33 GLP-1 prescribers in Weston, most listed as Family Medicine (11), Internal Medicine (10) and Internal Medicine, Endocrinology, Diabetes & Metabolism (8). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Pembroke Pines (43 providers), Davie (35 providers) and Plantation (36 providers).
Around the prescription in Weston
7 listed nearby
54 dietitians, 7 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 3 places to move are on record near Weston.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Weston

Weston, Florida has a population of 68,107 people. The adult obesity rate in Weston is an age-adjusted estimate of 24.8%, 4.8 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 8.8% of adults in Weston. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.5% of adults in Weston.

of Weston adults have obesity
24.8%
diagnosed diabetes
8.8%
no regular physical activity
18.5%

Age-adjusted estimates for Weston, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe science of Ozempic face
§ 05Support around Tirzepatide in Weston
6 fitness clubs

The prescription is one part. Here is the rest, in Weston.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Weston, FL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

My-Bodyfit Weston
FITNESS
5.0 on Google · 224 reviews
70 Indian Trace
Website
Hustle Driven
FITNESS
5.0 on Google · 38 reviews
140 Weston Rd
Website
F45 Training North Weston
GYM
5.0 on Google · 663 reviews
2575 Glades Cir Suite 1
Website
WIND ATHLTX
GYM
4.9 on Google · 284 reviews
1495 N Park Dr
Website
Freakin’ Fitness Weston (24/7)
FITNESS
4.9 on Google · 235 reviews
1728 N Commerce Pkwy
Website
Orangetheory Fitness
GYM
4.6 on Google · 177 reviews
1132 Weston Rd
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Julie Anda, MPH, RD, LD
RD
Registered dietitian
2950 Cleveland Clinic Blvd
Call 954-659-5000NPI 1477379923
Tracey Beek, MS, RD, LD/N
RD
Registered dietitian
2950 Cleveland Clinic Blvd
Call 954-659-5000NPI 1821877051
Antonella Behncke
RD
Registered dietitian
16300 Golf Club Rd Apt 213
Call 954-319-0546NPI 1043174097
Lais Botelho, MS, RD, LDN
RD
Registered dietitian
2950 Cleveland Clinic Blvd
Call 305-397-9371NPI 1578331922
Carmen Brain Urrunaga
RD
Registered dietitian
291 Landings Blvd
Call 954-290-4102NPI 1033848395
Meryl Brandwein, R.D./L.D.N
RD
Registered dietitian · Metabolic
916 Gulfstream Ct
Call 954-654-0877NPI 1194914895
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in Florida

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]